Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles.
Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles.
复制标题
环状 RNA 和肝细胞癌：具有诊断和预后作用的新表观遗传学参与者
DOI：
10.3389/fonc.2021.653717
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Wu H
中科院分区：
文献类型：
--
作者：
Aishanjiang K;Wei XD;Fu Y;Lin X;Ma Y;Le J;Han Q;Wang X;Kong X;Gu J;Wu H
肝细胞癌（HCC）是全球癌症相关死亡的主要原因之一。由于缺乏有效的诊断和预后生物标志物以及有效的治疗靶点，HCC患者的总体生存预后较差。环状RNA（Circular RNA）是一类新型的内源性非编码RNA，具有共价闭环结构，参与多种生理过程和病理疾病。最近的研究表明，circRNA参与HCC的诊断，预后，发展和耐药性，这表明circRNA可能是一类新的目标，以改善HCC的诊断，预后和治疗。事实上，一些人工circRNA已经被工程化，并显示出它们在治疗HCV感染和胃癌方面的治疗潜力。本文介绍了circRNA作为肝癌诊断和预后的生物标志物以及作为肝癌治疗靶点的潜力，并讨论了circRNA研究面临的挑战和应用前景。
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Due to the lack of potent diagnosis and prognosis biomarkers and effective therapeutic targets, the overall prognosis of survival is poor in HCC patients. Circular RNAs (circRNAs) are a class of novel endogenous non-coding RNAs with covalently closed loop structures and implicated in diverse physiological processes and pathological diseases. Recent studies have demonstrated the involvement of circRNAs in HCC diagnosis, prognosis, development, and drug resistance, suggesting that circRNAs may be a class of novel targets for improving HCC diagnosis, prognosis, and treatments. In fact, some artificial circRNAs have been engineered and showed their therapeutic potential in treating HCV infection and gastric cancer. In this review, we introduce the potential of circRNAs as biomarkers for HCC diagnosis and prognosis, as therapeutic targets for HCC treatments and discuss the challenges in circRNA research and chances of circRNA application.
登录
查看更多内容
环状 RNA 测序确定 CircASAP1 是肝细胞癌转移的关键调节因子。
影响因子：
13.5
作者：
Hu, Zhi-Qiang;Zhou, Shao-Lai;Zhou, Jian
通讯作者：
Zhou, Jian
环状 RNA circMET 通过 miR-30-5p/snail/DPP4 轴驱动肝细胞癌的免疫抑制和抗 PD1 治疗耐药性。
影响因子：
37.3
作者：
Huang, Xiao-Yong;Zhang, Peng-Fei;Shi, Guo-Ming
通讯作者：
Shi, Guo-Ming
影响因子：
5.2
作者：
Artemaki PI;Scorilas A;Kontos CK
通讯作者：
Kontos CK
DOI：
10.3390/diseases3040360
发表时间：
2015-12-01
期刊：
Diseases (Basel, Switzerland)
影响因子：
--
作者：
Ikeda M;Mitsunaga S;Ohno I;Hashimoto Y;Takahashi H;Watanabe K;Umemoto K;Okusaka T
通讯作者：
Okusaka T
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen